Genentech Returns Long-Acting Growth Hormone Candidate To Altus
This article was originally published in The Pink Sheet Daily
Genentech/Roche anti-cancer drug Avastin wins European approval for first-line use in advanced kidney cancer.
You may also be interested in...
Oncologic Drugs Advisory Committee expresses concerns about overall survival, toxicity and study conduct.
The growth hormone candidate offers once-weekly dosing for adults and children.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.